Skip to main content

JOHNSON & JOHNSON

For the period ended Mar 12, 2025. Filed Mar 12, 2025.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Mar 12, 2025 · Filed Mar 12, 2025

JNJ$276.22+1.4%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrantý

Filed by a Party other than the Registranto

Check the appropriate box:

oPreliminary Proxy Statement
oConfidential, for the Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
ýDefinitive Proxy Statement
oDefinitive Additional Materials
oSoliciting Material under § 240.14a-12

Johnson & Johnson

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than Registrant)

Payment of Filing Fee (Check all boxes that apply):

ýNo fee required.
oFee paid previously with preliminary materials.
oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-(6)(i)(4) and 0-11.

March 12, 2025

Notice of Annual Meeting & Proxy Statement

TimeThursday, April 24, 202510:00 a.m., Eastern TimeVotingYou are eligible to vote if you were a shareholder of record at the close of business on February 25, 2025. Ensure that your shares are represented at the meeting by voting in one of several ways:To vote via the internet prior to the meeting, go to the website listed on your proxy card or notice.
To vote by phone, call the telephone number specified on your proxy card or on the website listed on your notice.
If you received paper copies of your proxy materials, mark, sign, date and return your proxy card in the postage-paid envelope provided to vote by mail.
Whether or not you plan to attend the Annual Meeting, we call on you to vote and submit your proxy in advance of the meeting by using one of the methods described above.
Items of businessYou are invited to attend the Annual Meeting of Shareholders of Johnson & Johnson.The 2025 Annual Meeting will be held online in a virtual format.You or your proxyholder will be able to attend the 2025 Annual Meeting online, vote and submit questions by visiting www.virtualshareholdermeeting.com/JNJ2025 and using the 16-digit control number included on your notice, on your proxy card or in the voting instructions that accompanied your proxy materials.
1Elect the 11 nominees named in this Proxy Statement to serve as Directors for the coming year.
2Vote, on an advisory basis, to approve named executive officer compensation.
3Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025.
4-5Vote on the two shareholder proposals contained in this Proxy Statement, if properly presented at the Annual Meeting.
Transact such other matters as may properly come before the Annual Meeting and at any adjournment or postponement of the Annual Meeting.

By order of the Board of Directors,

Marc Larkins

Worldwide Vice President, Corporate Governance

Corporate Secretary

2025 Proxy Statement1

Important notice regarding the availability of Proxy Materials for the Annual Meeting of Shareholders of Johnson & Johnson

to be held on April 24, 2025.

The Proxy Statement and Annual Report to Shareholders are available at

www.investor.jnj.com/asm

2

Table of contents

5A message from our Lead Director
6Living into Our Credo
82025 Proxy Statement – summary
13Board of Directors and corporate governance
ITEM 1: Election of Directors
132025 Board nominees
14Director nomination process and Board refreshment
16Nominee skills, expertise and background
17Board nominee biographies
23Corporate governance
23Corporate governance highlights
26Board structure and operations
35Oversight of our Company
41Shareholder engagement
43Related person transactions and Director independence
46Director compensation
46Fiscal 2025 non-employee Director compensation
46Fiscal 2024 non-employee Director compensation
48Director compensation policies and practices
48Deferred fee plan for Directors
48Additional arrangements
49Stock ownership guidelines for non-employee Directors
49Stock ownership information
49Security ownership of certain beneficial owners, officers and Directors
52Compensation of executives
ITEM 2: Advisory vote to approve named executive officer compensation
53A message from our Compensation & Benefits Committee
54Compensation Committee report
55Compensation discussion and analysis
562024 Executive compensation summary
612024 Executive compensation
68Compensation decisions for 2024 performance
70NEO performance and compensation summaries
74Executive compensation decision process
78Additional information concerning executive compensation
81Compensation policies and practices
82Compensation decisions for 2023 performance
83Reconciliation of non-GAAP performance measures
86Executive compensation tables
86Reconciliation of our CEO's 2024 total direct compensation to the 2024 summary compensation table
892024 Summary compensation table
952024 Grants of plan-based awards
992024 Outstanding equity awards at fiscal year-end
1022024 Option exercises and stock vested
1022024 Pension benefits
1042024 Non-qualified deferred compensation
1072024 Potential payments upon termination
110Ratio of the annual total compensation of the median-paid employee to the CEO
111Pay versus performance
119Equity grant practices
120Audit matters
120Audit Committee report
ITEM 3: Ratification of appointment of independent registered public accounting firm
122Selection and engagement of audit firm
122Audit and non-audit fees
123Pre-approval of audit and non-audit services
ITEMS 4-5: Shareholder proposals
129Other information
135Non-GAAP reconciliation
Index of frequently requested information (alphabetical)
130Annual Meeting attendance
82Anti-pledging, hedging policy
122Auditor fees
122Auditor tenure
15Board and Committees evaluation
26Board leadership structure
34Board meeting attendance
110CEO pay ratio
70CEO performance evaluation
75Compensation consultant
56Compensation summary
23Corporate governance highlights
38Cybersecurity
17Director biographies
44Director independence
24Director overboarding policy
14Director qualifications
39Environmental, social and governance
82Exec. comp. recoupment policies
39Human capital management
27Lead Director duties and responsibilities
63Long-term incentives
130Notice and access
37Product quality and patient safety
61Pay for performance
76Peer group comparisons
68Perquisites
39Political spending oversight
23Proxy access
43Related person transactions
35Risk oversight
107Severance benefits
41Shareholder engagement
124Shareholder proposals
Stock ownership requirements:
49for non-employee Directors
81for executive officers
129Voting
134Websites and resources
2025 Proxy Statement3

Our Credo

We believe our first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality. We must constantly strive to provide value, reduce our costs and maintain reasonable prices. Customers' orders must be serviced promptly and accurately. Our business partners must have an opportunity to make a fair profit.

We are responsible to our employees who work with us throughout the world. We must provide an inclusive work environment where each person must be considered as an individual. We must respect their diversity and dignity and recognize their merit. They must have a sense of security, fulfillment and purpose in their jobs. Compensation must be fair and adequate and working conditions clean, orderly and safe. We must support the health and well-being of our employees and help them fulfill their family and other personal responsibilities. Employees must feel free to make suggestions and complaints. There must be equal opportunity for employment, development and advancement for those qualified. We must provide highly capable leaders and their actions must be just and ethical.

We are responsible to the communities in which we live and work and to the world community as well. We must help people be healthier by supporting better access and care in more places around the world. We must be good citizens - support good works and charities, better health and education, and bear our fair share of taxes. We must maintain in good order the property we are privileged to use, protecting the environment and natural resources.

Our final responsibility is to our stockholders. Business must make a sound profit. We must experiment with new ideas. Research must be carried on, innovative programs developed, investments made for the future and mistakes paid for. New equipment must be purchased, new facilities provided and new products launched. Reserves must be created to provide for adverse times. When we operate according to these principles, the stockholders should realize a fair return.

4

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.